Loading data for LUCD — first visit, this takes a few seconds.
Lucid Diagnostics Inc. (LUCD)
NasdaqCM: LUCD
· Real-Time Price · USD
1.01
+0.02 (2.02%)
At close: Aug 18, 2026, 3:59 PM
Lucid Diagnostics Inc. (LUCD) Stock Price, Analysis & Data
2.02% (1D)
| Bid | n/a |
| Market Cap | 192.86M |
| Revenue (ttm) | 5.45M |
| Net Income (ttm) | -65.01M |
| Beta | 1.08 |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.31 |
| P/B (ttm) | -27.30 |
| P/S (ttm) | 35.42 |
| Earnings Date | Nov 11, 2026 |
| Ask | n/a |
| Volume | 1,033,511 |
| Avg. Volume (20D) | 1,437,283 |
| Open | 0.98 |
| Previous Close | 0.99 |
| Day's Range | 0.97 - 1.03 |
| 52-Week Range | 0.86 - 1.63 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a tes...
Industry Medical Devices
Sector Healthcare
IPO Date Oct 14, 2021
Employees 82
Stock Exchange NasdaqCM
Ticker Symbol LUCD
Website https://www.luciddx.com
Financial Performance
In 2025, Lucid Diagnostics's revenue was 4.71M, an increase of 8.28% compared to the previous year's 4.35M. Earnings were -58.01M, an increase of 27.41%.
Financial StatementsEarnings Surprise
Lucid Diagnostics has released their quarterly earnings on Aug 12, 2026:
Lucid Diagnostics Inc. is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2